US regulators on Friday approved Harvoni, a daily pill to treat hepatitis C that is simpler to administer than long-standing treatments but that carries a steep price tag.
Oct 10, 2014
3.5 / 5 (4) | 1
A new national clinical trial found HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy. The finding is important for patients who are not eligible for treatment with efavirenz, ...
Oct 06, 2014
5 / 5 (1) | 0